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Sarcoidosis is an inflammatory multisystem disorder of 
unknown etiology with a worldwide distribution that can af-
fect lungs, lymphatic system, skin, liver, eyes, and nervous sys-
tem1. We owe the first recorded and illustrated description of 
sarcoidosis to Jonathan Hutchinson in 1878, when he report-
ed a patient with a dermatologic disease, which comprised 
purplish, symmetric, and non-tender skin plaques, initially 
considered a manifestation of gout2. The term sarcoidosis 
comes from histological studies performed by Cesar Boeck, 
in 1899, who described pathological findings of skin lesions 
that resembled those of sarcoma, which he called ‘sarkoid’ or 
‘sarcoma-like’3. Involvement of the nervous system was first 
recognized, in 1905, by Winkler, and, in 1909, Heerfordt de-
scribed three patients in the context of facial nerve palsies, 
uveitis, parotid enlargement, and fever1,3. 
Neurosarcoidosis (NS) may involve any part of the ner-
vous system with acute and chronic courses1,4. Cranial 
nerves, hypothalamus, and pituitary gland are the most 
commonly regions involved, but meninges, parenchyma, 
brainstem, and spinal cord may also be affected4. Clinical 
differentiation from other neurological diseases may be dif-
ficult when an isolated involvement of the nervous system 
is present3,4. In this review, we highlighted its clinical forms, 
pathogenesis, and treatment guidelines for NS, as guidance 
for general neurologists.
neUROLOGiCaL ManiFesTaTiOns OF saRCOidOsis
Neurologic manifestations are found in 5 to 20% of cases 
and symptoms may be mild or even severe, requiring a more 
aggressive intervention. About one-half of patients with NS 
can develop neurologic manifestations before systemic sar-
coidosis is evident5. 
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absTRaCT
Neurosarcoidosis (NS) more commonly occurs in the setting of systemic disease. The diagnosis is based on a clinical history suggestive of 
NS, presence of noncaseating granulomas, and supportive evidence of sarcoid pathology, laboratory, and imaging studies. NS could involve 
any part of the nervous system and often demands high doses of steroids for symptom control. It presents low response to isolated steroids 
administration and frequently requires immunosuppressive agents. In NS, lymphocytes are polarized toward an excessive Th1 response, 
leading to overproduction of TNF-alpha and INF-gama, as well as lL-2 and IL-15. Infliximab, a chimeric monoclonal antibody that neutralizes 
the biological activity of TNF-alpha, is a new option in the NS treatment. We revised pathophysiology, clinical manifestations, diagnostic work 
up, and treatment of NS as guidance for the general neurologist.
Key words: sarcoidosis, neurosarcoidosis, methotrexate, azathioprine, cyclophosphamide, infliximab.
ResUMO
A neurosarcoidose (NS) ocorre frequentemente no contexto de doença sistêmica. O diagnóstico é baseado na história clínica sugestiva 
de NS, presença de granulomas não-caseosos e achados anatomopatológicos, laboratoriais e radiológicos de sarcoidose. A NS causa 
manifestações neurológicas variadas, que apresentam, em geral, baixa resposta ao corticoide isoladamente e, portanto, necessitam 
uso de imunossupressores. Na NS, os linfócitos estão polarizados para resposta Th1 excessiva, levando à produção aumentada de 
TNF-alfa e IFN-gama, assim como IL-2 e IL-15. Infliximabe, um anticorpo monoclonal quimérico que neutraliza a atividade biológica do 
TNF-alfa, é uma nova opção no tratamento da NS. Revisou-se a fisiopatologia, as manifestações clínicas, o diagnóstico e o tratamento 
da NS para orientar neurologistas gerais.
Palavras-Chave: sarcoidose, neurosarcoidose, metotrexato, azatioprina, ciclofosfamida, infliximabe.
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Hydrocephalus and chronic meningitis
Meningitis may present as a single episode or as a recur-
rent or chronic course. Cerebrospinal fluid (CSF) pleocyto-
sis often occur in the setting of other manifestations, such as 
cranial neuropathy, myelopathy, mass lesions, or other focal 
neurologic manifestations. Granulomata in the fourth ven-
tricle could be responsible for hydrocephalus, which may re-
quire urgent treatment6. 
Central nervous system
NS patients with headache may present meningitis, in-
creased intracranial pressure or granulomatous mass lesions, 
which may mimic demyelination or neoplasm lesions7. In pa-
tients with intraxial lesions, seizures are found in 5 to 22%, 
including generalized, complex partial and myoclonic sei-
zures8. Hypothalamic and pituitary involvement is a char-
acteristic feature of NS, and the posterior pituitary is more 
commonly affected than the anterior. Polydipsia and polyuria 
may be the presenting symptoms of NS secondary to diabe-
tes insipidus. Other manifestations include hypothyroidism, 
amenorrhea, galactorrhea, sleep disorders, weight gain, tem-
perature dysregulation, and personality changes. The possi-
bility of endocrine dysfunction should always be investigated 
in the context of nonspecific complaints such as weight loss, 
fatigue and generalized weakness9.
Patients with NS may present white matter abnormalities 
on the magnetic resonance imaging (MRI) (Fig 1) and pro-
gressive multifocal leukoencephalopathy should be consid-
ered as a differential diagnosis10. Myelopathy in NS is unusu-
al, often evolving over weeks to months, with radiculopathy 
or long tract dysfunction. Intramedullary sarcoidosis may 
present focal enlargement of the cord with gadolinium en-
hancement. Progressive motor dysfunction may even mimic 
anterior horn syndrome10. 
Involvement of basal ganglia may lead to movement dis-
orders, with rare reports linking sarcoidosis to Parkinsonism 
and generalized chorea11. Stroke, subarachnoid hemor-
rhage, or intraparenchymal hemorrhage are quite rare in NS 
and may result from blood vessels involvement by sarcoid 
granulomas9,11. Most NS patients with increased intracrani-
al pressure present mass lesions, meningitis, or venous sinus 
thrombosis. In despite of that, few reports described pseudo-
tumor cerebri due to NS12. 
neuropsychiatric manifestations
Patients with sarcoidosis and extensive central ner-
vous system (CNS) involvement may develop dementia, 
psychoses, depression, poor concentration, hallucina-
tions, and encephalopathy. Neuropsychiatry symptoms 
(NPS) develop months, sometimes presenting a relapse-
remitting course. They can be found in sarcoid patients 
without evident CNS involvement. However, when NPS 
are found, CSF analysis is frequently abnormal, disclosing 
pleocytosis or increased protein13. 
Cranial and peripheral neuropathy
The most common cranial neuropathy in NS is facial pal-
sy, which may represent an isolated manifestation or which 
can occur in the context of multiple cranial nerve involve-
ment. NS should be considered when multiple cranial nerves 
are affected or in patients with bilateral facial palsy. The optic 
nerve is involved in up to 38% of NS patients and some may 
present a progressive and painless monocular visual loss, 
sometimes with papilledema or optic atrophy. Less often, an 
acute or subacute visual loss may occur. Retrobulbar optic 
neuritis mimics multiple sclerosis. Approximately 20% of pa-
tients have uveitis, usually bilateral, granulomatous that may 
be anterior (more common) or posterior14,15. 
Sarcoid patients may present hearing loss or vestibu-
lar dysfunction due to acoustic neuropathy. Lower cranial 
nerves are more affected than those responsible for extraoc-
ular movements (III, IV, and VI), determining dysphagia or 
dysarthria16. 
Involvement of the peripheral nerves is a well-recognized 
feature of NS, occurring in up to 20% of patients. Most of them 
present depressed tendon reflexes or minor sensory changes, 
although severe weakness may be found. The clinical presenta-
tions mainly include symmetrical distal neuropathy, monon-
europathy, mononeuritis multiplex, and acute or chronic de-
myelinating polyneuropathy. The mechanism of nerve injury 
is unclear, with evidence for both axonal injury and demyeli-
nation process. Considering that some NS patients have pre-
sented chronic inflammatory demyelinating polyneuropathy, 
Fig 1. Brain magnetic resonance images of patients with 
neurosarcoidosis. A: hydrocephalus; B: meningeal thickening 
involving sphenoid wings and temporal lobes; C: meningeal 
thickening involving cavernous sinus with gadolinium 
enhancement; D: involvement of the right cerebellar 
hemisphere; E: leukoencephalopathy of anterior temporal 
lobes; F: white-matter hyperintensities in cortico-subcortical 
regions of frontal lobes suggestive of vasculitis.
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some authors believe that cytokines and immune factors may 
also play a role in nerve injury17. Peripheral neuropathy may be 
associated with myositis or CNS involvement.
Myopathy
Asymptomatic involvement of the skeletal muscle by sar-
coid granulomas may occur in more than 50% of patients 
with sarcoidosis. Only 1–2% of the patients present symp-
tomatic muscle disease. Three distinct myopathy clinical pre-
sentations are recognized: acute myositis, nodular form, and 
chronic form. The most common of them is the chronic form, 
which presents slowly progressive weakness and normal cre-
atine phosphokinase levels, whereas acute myositis is rarely 
found. Patients with the nodular form may present palpable 
nodules. MRI and muscle imaging with gallium scanning pro-
vide more information for establishing diagnosis; however, 
muscle biopsy may be required for diagnosis9,11.  
PaTHOPHYsiOLOGY
The etiology of NS is multifactor, involving genetic predis-
position, environmental and individual factors. The ACCESS 
study demonstrated that agricultural employment, mold or 
mildew, musty odors at work, and pesticide-using industries 
are modestly associated with sarcoidosis risk (OR=1.5)18-20. 
On the other hand, tobacco was negatively associated with 
sarcoidosis18-20. Research into specific microbial etiologies 
showed that mycobacterial DNA and protein antigens are 
present in sarcoidosis tissues and are the target of T and B 
cell responses, suggesting some important etiologic factors18. 
It is speculated that deposition of microbial antigens and in-
soluble particules aggregates with specific host proteins in 
granulomas, generating an antigenic stimulus, followed by 
T-cell and macrophage activation via a classic major histo-
compatibility complex (MHC) II-mediated pathway21. 
The lymphocytes are polarized toward an excessive Th1 re-
sponse, leading to overproduction of TNF-alpha and INF-gama, 
as well as lL-2 and IL-15. The production of IL-12 and 18 also is 
increased, which enhances IFN-gama production and induces 
differentiation of Th0 precursors into active Th1 lymphocytes, 
perpetuating the response21. The CD4+ lymphocytes are central 
to the pathogenesis of sarcoidosis, triggering the granuloma for-
mation18. These basic immunologic features (Th1 polarization, 
oligoclonal T-cell expansions) are found in patients with sarcoi-
dosis, despite clinical manifestations.
Genetic linkage studies have identified the butyrophi-
lin-like 2 gene (BTNL2), localized in the MHC region and 
involved in T-lymphocyte activation and regulation, as a 
susceptibility factor for the development of sarcoidosis18,19. 
Human leukocyte antigens (HLAs) DR subtype of class 2 
antigens is associated with many inflammatory conditions, 
including sarcoidosis. HLA-DRB1*03, HLA-DRB1*11, HLA-
DRB1*12, HLA-DRB1*14, and HLA-DRB1*15 have been as-
sociated with an increased risk of developing the disease. 
HLA-DRB1*03 has been found to be associated with Löfgren 
syndrome, an acute form of sarcoidosis19.
diaGnOsTiC wORK UP
NS should be suspected in patients with documented sar-
coidosis that present neurologic complaints. In 50% of the cas-
es, neurological symptoms begin at the first signs of systemic 
disease22. The diagnosis is based on evidence of a clinical his-
tory suggestive of NS, exclusion of other conditions capable of 
producing noncaseating granulomas, presence of noncaseat-
ing granulomas, and supportive evidence of sarcoid pathology, 
laboratory and imaging studies15. Zajicek et al. established a 
classification to the diagnosis, according to Table 115,22.
It is important to determine whether sarcoidosis occurs 
as a systemic disease or if it is restricted to the CNS. For that 
purpose, one might use the Kveim-Siltzbach procedure, rare-
ly available in Brazil, which consists of an intradermal injec-
tion of heat-treated homogenate derived from sarcoid tissue. 
The development of a noncaseating granuloma at the injec-
tion site constitutes a positive response, but the sensitivity 
is limited, between 60 to 90%3. Chest radiography, thoracic 
computer tomography scan, and pulmonary function tests 
may reveal intra-thoracic involvement, which is found in up 
to 90% of the patients1. Routine laboratory tests may show 
hyperglobulinemia, hypercalcemia or elevation of alkaline 
phophatase3. Elevated levels of serum angiotensin-convert-
ing-enzyme (ACE) are present in 24 to 76% of the patients23. 
Despite its poor predictive value, ACE remains the only se-
rological marker of sarcoidosis. ACE activity in bronchoalve-
olar lavage (BAL) is generally considered a good marker of 
sarcoidosis severity with higher prognostic value than serum 
Possible: the clinical syndrome and neurorradiologic evaluation are suggestive of NS. Infection and malignancy were not rigorously 
excluded or there is no pathologic confirmation of systemic sarcoidosis
Probable: the clinical syndrome and neurorradiologic evaluation are suggestive of NS and differential diagnoses have been made, 
especially malignancy and infection. There is pathologic evidence of sarcoidosis
Definite: Probable diagnosis + supportive nervous system pathology or response to therapy for NS over a one- to two-year observation period
NS: neurosarcoidosis.
Table 1. Classification of definite, probable, and possible NS.
296 Arq Neuropsiquiatr 2012;70(4):293-299
ACE24. In addition, BAL can be used as an adjunctive mea-
sure to support the diagnosis of sarcoidosis, by demonstrat-
ing a cell pattern typical of lymphocytic alveolitis (lympho-
cyte count greater than 15%) and a T-cell CD4+/CD8+ ratio 
over 3.5, although it is present in 50% of patients22,24.
Whole body gallium scan, muscle magnetic resonance 
imaging, and whole body fluorodeoxyglucose positron emis-
sion tomography (PET) are useful approaches to search for 
systemic sarcoidosis when initial investigation is unreveal-
ing25. Usually, obtaining tissue specimens that show noncase-
ating granulomas best supports the diagnosis of sarcoidosis. 
Endobronchial ultrasound guided transbronchial needle as-
piration of mediastinal lymph nodes has facilitated diagno-
sis, often eliminating the need for more invasive procedures, 
such as mediastinoscopy22. 
For evaluating neurologic manifestations, the preferred 
imaging technique is MRI. T1-weighted images are useful to 
evaluate the optic chiasm, hydrocephalus, and spinal cord 
enlargement. Areas of increased intensity in T2-weighted im-
ages and FLAIR can be seen especially in the periventricu-
lar distribution. Gadolinium is useful to evaluate leptomen-
ingeal involvement, parenchymal abnormalities (nodular or 
visual pathway enhancement), and cranial nerve lesions22. 
Fluorodeoxyglucose PET imaging may reveal areas of hyper 
or hypometabolism within the CNS, which combined with 
areas of hypermetabolism on systemic PET may be elucida-
tive to NS diagnosis22,24. Fig 2 shows an algorithm to investi-
gate NS suspected cases.
CSF analysis can be helpful, although not specific. The 
majority of patients, particularly those with meningeal in-
volvement, present mononuclear pleocytosis ranging from 10 
to 100 cells/mm3, glucose as low as 30 mg/dL, and elevated 
opening pressure. Elevated CSF IgG titers and oligoclonal 
bands may be observed in some patients. Although ACE in 
the CSF is not specific of NS, it is most probably synthesized 
within the nervous system and seems to be especially useful 
in the monitoring of disease activity or treatment response1. 
Increased CSF lymphocytes CD4+: CD8+ ratio has also been 
observed in NS. However, it requires large numbers of viable 
lymphocytes, which are usually unavailable5.
Potential biomarkers to detect disease activity are under 
investigation. More recently, chitotriosidase, an enzyme in-
volved in the degradation of chitin, may induce overexpres-
sion of Th2 cytokines and forecast disease activity and prog-
nosis in sarcoidosis, with sensitivity over 90%5. IL-2 receptor 
may also be elevated in BAL of sarcoidosis patients with 
prognostic value and even higher levels in patients with ex-
trapulmonary involvement5,19. 
diFFeRenTiaL diaGnOsis
Differential diagnosis in NS depends on the clinical pre-
sentation. The presence of multisystem disease usually 
helps establishing the diagnosis, especially when patholog-
ical analyses showing sarcoid features are available at least 
from one site. It is important to rule out infectious diseases, 
neoplasms, and other autoimmune inflammatory disorders. 
Clinical manifestations and also MRI-based findings may 
guide the investigation (Table 2).
In the setting of subacute or chronic meningitis with 
headache, cranial neuropathies and constitutional symp-
toms, CSF analysis is mandatory. PCR for herpes family vi-
ruses have high sensitivity and specificity26. On the other 
hand, PCR for tuberculosis have a variable and otherwise low 
sensitivity, but high specificity27,28. Fungal and tuberculosis 
(TB) stains and cultures, immunologic analysis for fungal an-
tigens, and oncotic cytology are also important. Thickening 
and enhancement of the leptomeninges of patients with NS 
are virtually indistinguishable from those seen in tuberculo-
sis or lymphoma29. If dural involvement occurs, one should 
consider meningioma, dural metastasis, lymphoma, and id-
iopathic hypertrophic cranial pachymeningitis.
TB and sarcoid meningitis classically have predilection 
for basal involvement and may cause multiple cranial neu-
ropathies. However, syphilis, lymphoma, viral and fungal 
meningitis may also involve such region4,30,31. When facial pal-
sy, either uni or bilaterally, is present, borreliosis, Fisher and 
Guillain-Barré syndrome should be considered, as well as 
HIV infection, mononucleosis, postinfluenza, syphilis, acute 
porphyria, amyloidosis, and multiple sclerosis4,32. The differ-
ential diagnosis of isolated optic neuropathy includes optic 
nerve glioma, optic neuritis or involvement of dural nerve 
sheath by meningioma15. Sarcoidosis may also affect orbital 
fat, extrinsic ocular muscles or lacrimal glands mimicking or-
bital pseudotumor33. Fig 2. Algorithm for investigation of suspected neurosarcoidosis.
MRI: magnetic resonance image; CSF: cerebral spinal fluid; NS: 
neurosarcoidosis; ACE: angiotensin converting-enzyme.
Clinical history consistent with sarcoidosis?
MRI and CSF suggestive of NS?
Exclusion of conditions capable of producing
noncaseating granulomas?
Suggestive laboratory ﬁndings (high levels of 
ACE/hypercalciuria) and/or compatible 
thoracic computer tomography?
Endobronchial ultrasound guided
transbronchial needle aspiration of
mediastinal lymph nodes
Mediastinoscopy
Whole body gallium imaging
Yes
No
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Involvement of hypothalamic and pituitary dysfunction 
in NS may mimic pituitary adenoma, Rathke cleft cyst, and 
craniopharyngioma. However, polyuria and polydipsia due to 
diabetes insipidus or evidence of dysfunction of both ante-
rior and posterior pituitary lobes are less frequently associ-
ated with tumors32. Isolated infundibulum involvement seen 
as thickening and enhancement on T1-weighted MRI images 
may also be found in histiocytosis29. 
Intracranial mass lesions, presenting seizures or focal 
deficits, should be differentiated from primary and second-
ary tumors or tumecfative demyelination. In sarcoidosis, en-
hancing mass lesions are usually associated with adjacent 
leptomeningeal involvement. Hypointensity on NS lesions 
T2-weighted images may also be found in lymphoma or hy-
percellular metastases. Central necrosis is more commonly 
seen in neoplasms4,9,29.
TReaTMenT
Isolated cranial nerve abnormalities and aseptic menin-
gitis are frequent monophasic presentations and are at low 
risk for progression, with the exception of being occasional 
cases of progressive optic neuropathy34,35. Such manifesta-
tions usually present good response to short steroid course. 
However, patients who have parenchymal disease, seizures, 
mass lesions, leptomeningeal involvement with multiple cra-
nial nerve abnormalities, spinal cord disease, and hydroceph-
alus often experience a chronic remitting-relapsing course36. 
The development of hydrocephalus due to chronic meningi-
tis may be an ominous sign37. These severe manifestations of-
ten require high dose and prolonged course of steroids38. 
Although steroids have been the initial option, many pa-
tients require alternative treatments due to steroid intoler-
ance or persistent disease activity. Three studies that as-
sessed the response to steroids alone showed that less than 
40% of the patients stabilized or improved5,15,37,38. The report 
by Scott et al.37 selected patients for early aggressive immu-
nosuppressive therapy if they ‘presented with severe CNS (in-
tracranial lesions, hydrocephalus, myelopathy, seizures, or 
encephalopathy).’ Among the patients selected to receive ste-
roids alone, 35% improved on this regimen, whereas 69% im-
proved with immunosuppressive agents. Given the reports of 
treatment failure with steroid therapy in many patients and 
the toxic effects associated with long-term steroid use, cen-
ters with experience in treating NS often select patients with 
severe disease for treatment with steroids and alternative im-
munosuppressive agents (combination therapy) at the time 
of initial diagnosis36-38. 
We reviewed the most common prescribed agents for the 
treatment of NS and proposed a treatment strategy based on 
current studies from different centers specialized in sarcoi-
dosis and on our own experience (Fig 3).
steroids
Steroids remain the mainstay of treatment for NS5,15,36,37,39. 
They are most useful early in the treatment since they can 
lead to rapid reduction of the inflammation and the mass 
effect36. For severe manifestations, steroids are started at 
1 mg/kg or as a pulse of methylprednisolone 1,000 mg/day 
for three days, followed by tapering. For myopathy, facial 
palsy, and neuropathy, they are started at 0.5 mg/kg and 
maintained from two to four weeks, followed by tapering. 
Patients should be monitored for development of diabetes, 
Presentation Differential diagnosis
Meningitis Infections: bacterial, fungal, HIV and other viruses, TB, 
syphilis, borreliosis, Whipple’s disease
Inflammatory diseases: SLE, BD, SS
Tumors: lymphoma, carcinomatous meningitis
Cranial and/or peripheral neuropathy Infections: borreliosis, TB, fungal, syphilis
Tumors: meningioma, leptomeningeal metastases, gliomas
Inflammatory: Guillain-Barré syndrome, Fisher syndrome, SLE, SS, NBD
Demyelinating: MS
Systemic/Metabolic: amyloidosis, acute porphyria
Uveitis Infections: syphilis, toxoplasmosis
Inflammatory: SLE, SS, NBD
Myelopathy Demyelinating: MS
Infections: viral, fungal
Tumors: meningioma, lymphoma, carcinomatous metastasis, nerve sheath tumors, 
chloroma, hemangiopericytoma
Brain mass lesion Tumors: lymphoma, glioma, metastasis
Infections: toxoplasmosis, infectious granulomas
Demyelinating: Tumefactive demyelination
Brain white-matter lesions Demyelinating: MS
Antiphospholipid syndrome
Atherosclerotic vascular disease
Inflammatory: SLE, SS, NBD
Table 2. Differential diagnosis of NS based on clinical and imaging manifestations.
NS: neurosarcoidosis; TB: tuberculosis; SLE: systemic lupus erythematosus; NBD: Neuro-Behçet’s disease; SS: Sjoegren syndrome; MS: multiple sclerosis.
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Fig 3. Suggested treatment strategy for neurosarcoidosis. 
NS: neurosarcoidosis; PRED: prednisone; MTX: methotrexate; 
CFA: cyclophosphamide.
Treatment algorithm for Neurosarcoidosis
Mild NS
PRED
Tapper PRED <10 mg/day
Add MTX
Unable/
Relapse
PRED + MTX
or
Tapper <10 mg/day
Inﬂiximab or
PRED + CFA
Unable/
Relapse
Moderate/Severe NS
glucose intolerance, dislipemia, hypertension, and osteo-
porosis and frequently low steroids doses are required for 
more than one year. The goal is to maintain the patients 
with doses <10 mg/day40.
immunosuppressive agents
Methotrexate (MTX), azathioprine (AZA), and myco-
phenolate (MMF) are immunosuppressive agents common-
ly prescribed and equally effective. There are no randomized 
trials defining the optimal treatment for NS. MTX is the 
most common prescribed immunosuppressant, usually at 
7.5 to 15 mg/kg per week, followed by folic acid supplemen-
tation and requires bimonthly evaluation of liver function 
and blood cell counts with differential. AZA is prescribed at 
150 to 200 mg/day, and requires monthly liver function tests 
and blood cell counts. 
MMF is effective in treating cutaneous and renal sarcoi-
dosis. It is associated with less incidence of neutropenia than 
other cytotoxic agents; however, nausea and diarrhea can be 
dose-limiting adverse effects40. It is prescribed at 1,000 mg 
twice daily and it is occasionally used in association with inf-
liximab41. Although it is considered as a therapeutic option in 
NS, MMF is not effective in all NS manifestations, presenting 
low response for myopathy21. 
Cyclophosphamide (CFA) is reserved for refractory 
cases, according to previous studies36,38,42,43. It is started at 
0.5 mg/m2 until a maximum of 1,000 mg in monthly pulses 
for 6 to 12 months. Liver, renal function, blood cells count 
should be monitored monthly. CFA is associated with op-
portunistic and fungal infections, hemorrhagic cystitis, 
bone marrow aplasia, and higher cancer rates.
anti-TnF agents
Infliximab is a chimeric monoclonal antibody that neu-
tralizes the biological activity of TNF-alpha by binding to its 
soluble and transmembrane forms and inhibiting receptor 
binding44. Evidence for its use came from the finding of el-
evated TNF-alpha levels in lymph nodes and BAL of patients 
with sarcoidosis39 and by the demonstration that it is a cru-
cial cytokine in the establishment and maintenance of in-
flammation in several autoimmune disorders44. There are 23 
reports on the use of infliximab for refractory NS, sometimes 
in association with other immunosuppressive agents, such as 
CFA or MMF36,41,45,46. It is prescribed at 5 mg/kg at zero, two 
and six weeks and then repeated every eight weeks. Because 
infliximab may be associated with reactivation of tuberculo-
sis, chest X-rays and tuberculin tests are required before ini-
tiating therapy. Infliximab may also precipitate oncological 
and autoimmune complications, and it was also associated 
with high mortality rates in patients with advanced conges-
tive heart failure40,47.
Etarnecept, which is another TNF-alpha antagonist, pres-
ents lower response than infliximab for the treatment of sar-
coidosis. The reason for the enhanced efficacy of infliximab 
is not well understood, but it is believed that infliximab is 
highly specific for TNF-alpha, whereas etanercept also binds 
a related molecule, lymphotoxin-α ( formerly known as TNF-
beta). The molecular structure (an IgG antibody) of inflix-
imab allows it to initiate the classical complement pathway 
and causes cell lysis, whereas etanercept, a recombinant 
molecule attached to the Fc portion of human IgG1, cannot. 
Moreover, infliximab has been demonstrated to induce T-cell 
apoptosis, and etanercept has not47. 
Infliximab is a rescue option for patients resistant to CFA 
and there is evidence that it could be more effective than 
CFA42. For that reason, some specialists initiate infliximab 
before CFA for severe manifestations, which have already 
failed one immunosuppressive agent36,40,44.
PROGnOsis
Although treatment with steroids can improve MRI, clini-
cal responses may not correlate with radiological improve-
ment36. Mortality rates were 18% in a series of 37 patients and 
31% developed steroid side effects, related to the high dose 
of steroids and longer duration of therapy48. In another series 
of 54 patients, 10% developed progressive symptoms despite 
immunosuppressive treatment49. 
COnCLUsiOns
The diagnosis and management of NS remain challenging 
aspects of the disease. Most cases require immunosuppressive 
treatment due to the high rates of recurrence or incomplete 
response. Thus, immunosuppressive agents should be strongly 
considered at initial treatment. Biological agents such as inflix-
imab are good options in treating refractory cases.
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